Omnicare has been sold to Equistone

Omnicare is the third milestone transaction in the German healthcare market executed by Lincoln International during the last 18 months after advising on the sales of the Cannabis OTC business of Binorica to Canopy Growth and the sale of “Deutsche Fachpflege” to Advent International.

Omnicare, headquartered in Unterföhring, Germany, is the leading integrated player in Germany’s oncological outpatient market providing an ecosystem along the oncological value chain. Omnicare is active in three different market segments, namely, (i) specialist pharma distribution, (ii) services for compounding pharmacies and (iii) operation of outpatient medical care centers. In connection with these core services, Omnicare also provides trainings and quality control services, IT services and operates a medical clinic. Omnicare generates annual sales of more than Euro 675 million and employs approximately 200 people across three sites in Germany.

Equistone is an independent investment firm, which operates across France, Germany, Switzerland and the UK, investing as a strategic partner alongside management teams. Equistone currently invests from its more than Euro 2.8 billion fund, Equistone Partners Europe Fund VI.

Oliver Tamimi, Chief Executive at Omnicare, commented on the transaction: “In Equistone we have found a reliable and financially-strong new partner to help us realize the further development of our company. With Equistone’s support, we want to continue improving the local and outpatient care for cancer patients in Germany.”

Lincoln International acted as the exclusive M&A advisor to the shareholder consortium of Omnicare, preparing and managing a competitive M&A process, securing not only a very attractive economic outcome for the sellers but also identifying an ideal partner for Management to implement its long-term vision for Omnicare.

Share: